These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Pipamperone augmentation of clozapine and sodium valproate in refractory schizophrenia: a case report. Paraschakis A Clin Neuropharmacol; 2014; 37(2):60-1. PubMed ID: 24614672 [TBL] [Abstract][Full Text] [Related]
30. Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders. Thompson JV; Clark JM; Legge SE; Kadra G; Downs J; Walters JT; Hamshere ML; Hayes RD; Taylor D; MacCabe JH J Psychopharmacol; 2016 May; 30(5):436-43. PubMed ID: 26905920 [TBL] [Abstract][Full Text] [Related]
31. Augmentation of clozapine with ECT: a retrospective case analysis. Lally J; Breese E; Osman M; Hua Sim C; Shetty H; Krivoy A; MacCabe JH Acta Neuropsychiatr; 2021 Feb; 33(1):31-36. PubMed ID: 32967745 [TBL] [Abstract][Full Text] [Related]
32. Risperidone versus other atypical antipsychotic medication for schizophrenia. Gilbody SM; Bagnall AM; Duggan L; Tuunainen A Cochrane Database Syst Rev; 2000; (3):CD002306. PubMed ID: 10908551 [TBL] [Abstract][Full Text] [Related]
33. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074 [TBL] [Abstract][Full Text] [Related]
34. Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials. Siafis S; Schneider-Thoma J; Hamza T; Bighelli I; Dong S; Hansen WP; Davis JM; Salanti G; Leucht S BMJ Open; 2023 Feb; 13(2):e064504. PubMed ID: 36810167 [TBL] [Abstract][Full Text] [Related]
35. Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence. Correll CU; Rubio JM; Inczedy-Farkas G; Birnbaum ML; Kane JM; Leucht S JAMA Psychiatry; 2017 Jul; 74(7):675-684. PubMed ID: 28514486 [TBL] [Abstract][Full Text] [Related]
36. Newer atypical antipsychotic medication versus clozapine for schizophrenia. Tuunainen A; Wahlbeck K; Gilbody SM Cochrane Database Syst Rev; 2000; (2):CD000966. PubMed ID: 10796559 [TBL] [Abstract][Full Text] [Related]
37. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine. Krzystanek M; Krupka-Matuszczyk I Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416 [TBL] [Abstract][Full Text] [Related]
38. Clozapine versus typical neuroleptic medication for schizophrenia. Wahlbeck K; Cheine M; Essali MA Cochrane Database Syst Rev; 2000; (2):CD000059. PubMed ID: 10796289 [TBL] [Abstract][Full Text] [Related]
39. Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia? Karunakaran K; Tungaraza TE; Harborne GC J Psychopharmacol; 2007 Jun; 21(4):453-6. PubMed ID: 17050662 [TBL] [Abstract][Full Text] [Related]
40. [Augmentation of Clozapine With Paliperidone in Schizophrenia Patients With Partial Response to Treatment: A Case Series]. Kalenderoğlu A; Çelik M Turk Psikiyatri Derg; 2016; 27(1):57-62. PubMed ID: 27369686 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]